Jupiter Asset Management Ltd. cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 5.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 140,969 shares of the company's stock after selling 7,796 shares during the period. Jupiter Asset Management Ltd. owned 0.17% of IDEXX Laboratories worth $58,282,000 as of its most recent filing with the SEC.
Other institutional investors have also made changes to their positions in the company. FSA Wealth Management LLC bought a new position in shares of IDEXX Laboratories in the third quarter worth about $25,000. Rialto Wealth Management LLC bought a new position in shares of IDEXX Laboratories in the fourth quarter worth about $30,000. Retirement Wealth Solutions LLC bought a new position in shares of IDEXX Laboratories in the fourth quarter worth about $31,000. Ashton Thomas Securities LLC bought a new position in shares of IDEXX Laboratories in the third quarter worth about $37,000. Finally, Kestra Investment Management LLC bought a new position in shares of IDEXX Laboratories in the fourth quarter worth about $38,000. 87.84% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several brokerages recently issued reports on IDXX. Barclays boosted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Morgan Stanley reduced their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. StockNews.com downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday, March 7th. Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. Finally, Bank of America upped their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $533.75.
Read Our Latest Report on IDXX
IDEXX Laboratories Stock Performance
Shares of IDEXX Laboratories stock opened at $426.69 on Wednesday. The firm has a fifty day moving average of $438.11 and a two-hundred day moving average of $448.27. The stock has a market capitalization of $34.70 billion, a price-to-earnings ratio of 39.99, a PEG ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $552.20. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.
Insider Buying and Selling at IDEXX Laboratories
In related news, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP George Fennell sold 9,986 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.18% of the company's stock.
About IDEXX Laboratories
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
